Manejo de la hiperbilirrubinemia en el neonato de 35 o más semanas de gestación

1. Keren R, Tremont K, Luan X, Cnaan A. Visual assessment of jaundice in term and late preterm infants. Arch Dis Child Fetal Neonatal Ed. 2009; 94(5): F317–F322

2. Bhutani VK, Stark AR, Lazzeroni LC, et al; Initial Clinical Testing Evaluation and Risk Assessment for Universal Screening for Hyperbilirubinemia Study Group. Predischarge screening for severe neonatal hyperbilirubinemia infants who need phototherapy. J Pediatr. 2013;162(3): 477–482.e1

3. Maisels MJ, Baltz RD, Bhutani VK, et al; American Academy of Pediatrics Subcommittee on Hyperbilirubinemia. Management of hyperbilirubinemia in the newborn infant 35 or more weeks of gestation. Pediatrics. 2004; 114(1): 297–316

4. Perlman J, Volpe J. Bilirubin. In: Volpe J, Inder T, Barras D, et al, eds. Volpe’s Neurology of the Newborn. Philadelphia: Elsevier; 2018:730–762

5. American Academy of Pediatrics Steering Committee on Quality Improvement and Management. Classifying recommendations for clinical practice guidelines. Pediatrics. 2004; 114(3):874–877

6. Maisels MJ, Bhutani VK, Bogen D, Newman TB, Stark AR, Watchko JF. Hyperbilirubinemia in the newborn infant > or 35 weeks’ gestation: an update with clarifications. Pediatrics. 2009; 124(4):1193–1198

7. Bhutani VK, Johnson LH, Jeffrey Maisels M, et al. Kernicterus: epidemiological strategies for its prevention through systems-based approaches. J Perinatol. 2004;24(10): 650–662

8. Eggert LD, Wiedmeier SE, Wilson J, Christensen RD. The effect of instituting a pre hospital-discharge newborn bilirubin screening program in an 18-hospital health system. Pediatrics. 2006; 117(5):e855–e862

9. Kuzniewicz MW, Wickremasinghe AC, Wu YW, et al. Incidence, etiology, and outcomes of hazardous hyperbilirubinemia in newborns. Pediatrics. 2014; 134(3):504–509

10. Mah MP, Clark SL, Akhigbe E, et al. Reduction of severe hyperbilirubinemia after institution of predischarge bilirubin screening. Pediatrics. 2010;125(5): e1143–e1148

11. Slaughter JL, Kemper AR, Newman TB, et al. Technical report: Diagnosis and management of hyperbilirubinemia in the newborn infant 35 or more weeks of gestation. Pediatrics. 2022; 150(3):e2022058865

12. Northern California Neonatal Consortium. NCNC hyperbilirubinemia treatment guideline. Available at: https://phototherapy guidelines.com. Accessed February 15, 2022

13. Flaherman VJ, Maisels MJ; Academy of Breastfeeding Medicine. ABM clinical protocol #22: guidelines for management of jaundice in the breastfeeding infant 35 weeks or more of gestation —revised. Breastfeed Med. 2017;12(5): 250–257

14. Practice Bulletin No. Practice bulletin no. 181 summary: prevention of Rh D alloimmunization. Obstet Gynecol. 2017;130(2):481–483

15. Vats K, Watchko JF. Coordinating care across the perinatal continuum in hemolytic disease of the fetus and newborn: the timely handoff of a positive maternal anti-erythrocyte antibody screen. J Pediatr. 2019; 214: 212–216

16. Maayan-Metzger A, Schwartz T, Sulkes J, Merlob P. Maternal anti-D prophylaxis during pregnancy does not cause neonatal haemolysis. Arch Dis Child Fetal Neonatal Ed. 2001; 84(1):F60–F62

17. Chen YJ, Yeh TF, Chen CM. Effect of breast-feeding frequency on hyperbilirubinemia in breast-fed term neonate. Pediatr Int. 2015; 57(6):1121–1125

18. Maisels MJ, Clune S, Coleman K, et al. The natural history of jaundice in predominantly breastfed infants. Pediatrics. 2014; 134(2):e340–e345

19. Meek JY, Noble L; American Academy of Pediatrics, Section on Breastfeeding. Breastfeeding and the use of human milk. Pediatrics. 2022; 150(1):e2022057989

20. Feltner C, Weber RP, Stuebe A, Grodensky CA, Orr C, Viswanathan M. Breastfeeding Programs and Policies. Rockville, MD: Breastfeeding Uptake, and Maternal Health Outcomes in Developed Countries; 2018

21. Flaherman VJ, Schaefer EW, Kuzniewicz MW, Li SX, Walsh EM, Paul IM. Early weight loss nomograms for exclusively breastfed newborns. Pediatrics. 2015; 135(1):e16–e23

22. Wickremasinghe AC, Kuzniewicz MW, McCulloch CE, Newman TB. Efficacy of subthreshold newborn phototherapy during the birth hospitalization in preventing readmissions for phototherapy. JAMA Pediatr. 2018; 172(4):378–385

23. Ho NT, Li F, Lee-Sarwar KA, et al. Metaanalysis of effects of exclusive breastfeeding on infant gut microbiota across populations. Nat Commun. 2018; 9(1):4169

24. Urashima M, Mezawa H, Okuyama M, et al. Primary prevention of cow’s milk sensitization and food allergy by avoiding supplementation with cow’s milk formula at birth: a randomized clinical trial. JAMA Pediatr. 2019; 173(12):1137–1145

25. Patnode CD, Henninger ML, Senger CA, Perdue LA, Whitlock EP. Primary care interventions to support breastfeeding: updated evidence report and systematic review for the US preventive services task force. JAMA. 2016; 316(16):1694–1705

26. Johnson L, Bhutani VK, Karp K, Sivieri EM, Shapiro SM. Clinical report from the pilot USA kernicterus registry (1992 to 2004). J Perinatol. 2009; 29(suppl 1): S25–S45

27. Watchko JF. Hyperbilirubinemia in African American neonates: clinical issues and current challenges. Semin Fetal Neonatal Med. 2010; 15(3):176–182

28. Sgro M, Campbell D, Shah V. Incidence and causes of severe neonatal hyperbilirubinemia in Canada. CMAJ. 2006; 175(6):587–590

29. Wright JL, Davis WS, Joseph MM, Ellison AM, Heard-Garris NJ, Johnson TL. Eliminating race-based medicine [published online ahead of print May 2, 2022]. Pediatrics. 2022; doi: 10:1542/peds.2022-057998

30. Nkhoma ET, Poole C, Vannappagari V, Hall SA, Beutler E. The global prevalence of glucose-6-phosphate dehydrogenase deficiency: a systematic review and meta-analysis. Blood Cells Mol Dis. 2009;42(3):267–278

31. Kaplan M, Herschel M, Hammerman C, Hoyer JD, Stevenson DK. Hyperbilirubinemia among African American, glucose-6-phosphate dehydrogenase deficient neonates. Pediatrics. 2004; 114(2):e213–e219

32. Watchko JF, Kaplan M, Stark AR, Stevenson DK, Bhutani VK. Should we screen newborns for glucose-6-phosphate dehydrogenase deficiency in the United States? J Perinatol. 2013; 33(7): 499–504

33. Chinevere TD, Murray CK, Grant E Jr, Johnson GA, Duelm F, Hospenthal DR. Prevalence of glucose-6-phosphate dehydrogenase deficiency in US Army personnel. Mil Med. 2006; 171(9): 905–907

34. Okolie F, South-Paul JE, Watchko JF. Combating the hidden health disparity of kernicterus in black infants: a review. JAMA Pediatr. 2020; 174(12): 1199–1205

35. Kaplan M, Muraca M, Vreman HJ, et al. Neonatal bilirubin production-conjugation imbalance: effect of glucose-6-phosphate dehydrogenase deficiency and borderline prematurity. Arch Dis Child Fetal Neonatal Ed. 2005; 90(2): F123–F127

36. Nock ML, Johnson EM, Krugman RR, et al. Implementation and analysis of a pilot in-hospital newborn screening program for glucose-6-phosphate dehydrogenase deficiency in the United States. J Perinatol. 2011; 31(2): 112–117

37. MacDonald MG. Hidden risks: early discharge and bilirubin toxicity due to glucose 6-phosphate dehydrogenase deficiency. Pediatrics. 1995; 96(4 Pt 1): 734–738

38. Kaplan M, Hammerman C, Vreman HJ, Wong RJ, Stevenson DK. Severe hemolysis with normal blood count in a glucose-6-phosphate dehydrogenase deficient neonate. J Perinatol. 2008; 28(4):306–309

39. Nair PA, Al Khusaiby SM. Kernicterus and G6PD deficiency–a case series from Oman. J Trop Pediatr. 2003; 49(2): 74–77

40. Mukthapuram S, Dewar D, Maisels MJ. Extreme Hyperbilirubinemia and G6PD deficiency with no laboratory evidence of hemolysis. Clin Pediatr (Phila). 2016; 55(7):686–688

41. Greene DN, Liang J, Holmes DT, Resch A, Lorey TS. Neonatal total bilirubin measurements: Still room for harmonization. Clin Biochem. 2014; 47(12): 1112–1115

42. Lo SF, Doumas BT. The status of bilirubin measurements in US laboratories: why is accuracy elusive? Semin Perinatol. 2011; 35(3):141–147

43. Lo SF, Doumas BT, Ashwood ER. Performance of bilirubin determinations in US laboratories–revisited. Clin Chem. 2004; 50(1):190–194

44. Ahlfors CE, Parker AE. Bilirubin binding contributes to the increase in total bilirubin concentration in newborns with jaundice. Pediatrics. 2010; 126(3): e639–e643

45. Watchko JF, Spitzer AR, Clark RH. Prevalence of hypoalbuminemia and elevated bilirubin/albumin ratios in a large cohort of infants in the neonatal intensive care unit. J Pediatr. 2017; 188:280–286.e4

46. Kramer LI. Advancement of dermal icterus in the jaundiced newborn. Am J Dis Child. 1969; 118(3): 454–458

47. Moyer VA, Ahn C, Sneed S. Accuracy of clinical judgment in neonatal jaundice. Arch Pediatr Adolesc Med. 2000; 154(4): 391–394

48. Tayaba R, Gribetz D, Gribetz I, Holzman IR. Non invasive estimation of serum bilirubin. Pediatrics. 1998; 102(3):E28

49. Riskin A, Tamir A, Kugelman A, Hemo M, Bader D. Is visual assessment of jaundice reliable as a screening tool to detect significant neonatal hyperbilirubinemia? J Pediatr. 2008; 152(6):782–787, 787 e781–782

50. Newman TB, Liljestrand P, Escobar GJ. Jaundice noted in the first 24 hours after birth in a managed care organization. Arch Pediatr Adolesc Med. 2002;156(12):1244–1250

51. Engle WD, Jackson GL, Engle NG. Transcutaneous bilirubinometry. Semin Perinatol. 2014; 38(7):438–451

52. De Luca D, Jackson GL, Tridente A, Carnielli VP, Engle WD. Transcutaneous bilirubin nomograms: a systematic review of population differences and analysis of bilirubin kinetics. Arch Pediatr Adolesc Med. 2009; 163(11):1054–1059

53. Taylor JA, Burgos AE, Flaherman V, et al; Better Outcomes through Research for Newborns Network. Discrepancies between transcutaneous and serum bilirubin measurements. Pediatrics. 2015; 135(2):224–231

54. Hulzebos CV, Vitek L, Coda Zabetta CD, et al. Screening methods for neonatal hyperbilirubinemia: benefits, limitations, requirements, and novel developments. Pediatr Res. 2021; 90(2): 272–276

55. van den Esker-Jonker B, den Boer L, Pepping RM, Bekhof J. Transcutaneous bilirubinometry in jaundiced neonates: a randomized controlled trial. Pediatrics. 2016; 138(6):e20162414

56. Wainer S, Parmar SM, Allegro D, Rabi Y, Lyon ME. Impact of a transcutaneous bilirubinometry program on resource utilization and severe hyperbilirubinemia. Pediatrics. 2012; 129(1):77–86

57. Bhutani VK, Gourley GR, Adler S, Kreamer B, Dalin C, Johnson LH. Non invasive measurement of total serum bilirubin in a multiracial predischarge newborn population to assess

the risk of severe hyperbilirubinemia. Pediatrics. 2000; 106(2):E17

58. Maisels MJ, Ostrea EM Jr, Touch S, et al. Evaluation of a new transcutaneous bilirubinometer. Pediatrics. 2004; 113(6):1628–1635

59. Kolman KB, Mathieson KM, Frias C. A comparison of transcutaneous and total serum bilirubin in newborn Hispanic infants at 35 or more weeks of gestation. J Am Board Fam Med. 2007; 20(3):266–271

60. Rubaltelli FF, Gourley GR, Loskamp N, et al. Transcutaneous bilirubin measurement: a multicenter evaluation of a new device. Pediatrics. 2001; 107(6): 1264–1271

61. Konana OS, Bahr TM, Strike HR, Coleman J, Snow GL, Christensen RD. Decision accuracy and safety of transcutaneous bilirubin screening at intermountain healthcare. J Pediatr. 2021; 228:53–57

62. Engle WD, Jackson GL, Sendelbach D, Manning D, Frawley WH. Assessment of a transcutaneous device in the evaluation of neonatal hyperbilirubinemia in a primarily Hispanic population. Pediatrics. 2002; 110 (1 Pt 1):61–67

63. Slusher TM, Angyo IA, Bode-Thomas F, et al. Transcutaneous bilirubin measurements and serum total bilirubin levels in indigenous African infants. Pediatrics. 2004; 113(6):1636–1641

64. Olusanya BO, Imosemi DO, Emokpae AA. Differences between transcutaneous and serum bilirubin measurements in Black African neonates. Pediatrics. 2016; 138(3):e20160907

65. Maya-Enero S, Candel-Pau J, Garcia-Garcia J, Duran-Jorda X, López-Vilchez MA. Reliability of transcutaneous bilirubin determination based on skin color determined by a neonatal skin color

scale of our own. Eur J Pediatr. 2021; 180(2):607–616

66. Chimhini GLT, Chimhuya S, Chikwasha V. Evaluation of transcutaneous bilirubinometer (DRAEGER JM 103) use in Zimbabwean newborn babies. Matern Health Neonatol Perinatol. 2018; 4:1